Ocugen, Inc. - OCGN STOCK NEWS

Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri, CEO and Co-Founder, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 4, 2022. The event takes place at the Westin Grand Central Hotel in New York City, from 8:30 to 8:55 a.m. ET. A live webcast will be available for viewers. Ocugen focuses on developing innovative gene and cell therapies, aiming to improve health and address unmet medical needs globally. For more details, visit their website.

Ocugen enters into an exclusive license agreement with Washington University for the rights to develop and commercialize its intranasally delivered COVID-19 vaccine. The vaccine is authorized for emergency use in India and has the potential to reduce SARS-CoV-2 transmission and the emergence of new variants. Ocugen believes the vaccine can generate rapid local immunity and provide an alternative to injectable vaccines.

Ocugen announced on Sept. 16, 2022, that its Compensation Committee approved stock options and restricted stock units (RSUs) for five new hires, totaling 148,800 shares in stock options and 40,092 shares in RSUs. The options, granted at an exercise price of $2.17, have a ten-year term and vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. Ocugen focuses on novel gene and cell therapies and vaccines, aiming to improve health and address unmet medical needs.

Ocugen, Inc. announced the publication of a comprehensive review on BBV152, commercialized as COVAXIN™, highlighting its effectiveness against COVID-19 and its variants, particularly Delta and Omicron. The review published in Frontiers in Immunology emphasizes the vaccine's immunogenicity, safety, and efficacy. BBV152 shows 77.8% protection from symptomatic COVID-19 and over 95% seroconversion in pediatric populations. COVAXIN™ has been authorized in 28 countries and accepted by over 85 for travel, enhancing its global accessibility. The company is investigating its use in adults in the U.S.

Ocugen, a biotechnology company, announces that Chief Scientific Officer Arun Upadhyay will speak at the 3rd Annual Gene Therapy for Ophthalmic Disorders Conference from September 13-16 in Danvers, Massachusetts. Dr. Upadhyay's presentation, scheduled for September 14 at 9:15 a.m. ET, will focus on the Modifier Gene Therapy Approach for Retinitis Pigmentosa. This event highlights Ocugen's commitment to advancing innovative therapies for retinal diseases. The company is actively developing gene and cell therapies to improve patient outcomes globally.

Ocugen, a biotechnology company, announced that Dr. Shankar Musunuri will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. The chat is scheduled for September 12, 2022, from 3:30 – 4:00 p.m. ET at the Lotte New York Palace Hotel. A live video webcast will be available on the Ocugen investor site at the time of the event, with a replay archived for 90 days. Ocugen focuses on innovative gene and cell therapies and vaccines.

Ocugen, Inc. (NASDAQ: OCGN) announced the appointment of Robert J. Hopkins as Chief Medical Officer and Arun Upadhyay as Chief Scientific Officer. Dr. Hopkins brings over 25 years of experience in clinical research and has previously served as Chief Medical Officer at Adaptive Phage Therapeutics. Dr. Upadhyay transitions from Senior Vice President to lead the company’s R&D efforts. The leadership changes aim to enhance Ocugen's clinical programs and product development in gene therapies and vaccines, particularly for COVID-19 and retinal diseases.

Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, CEO and Co-Founder, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. A video webcast of the presentation will be available on demand starting at 7:00 a.m. ET for registered attendees and will be accessible on Ocugen's investor site for 90 days post-event. Ocugen focuses on developing innovative gene therapies, biologicals, and vaccines, particularly in retinal diseases and public health challenges.

Ocugen reported Q2 2022 financial results, highlighting significant milestones in its clinical programs. The Phase 2/3 COVAXIN™ trial is progressing, with positive data published supporting its use in children. The company's OCU400 gene therapy trial has completed dosing for Cohort 1, with plans to advance to Cohort 2. Ocugen introduced NeoCart®, a Phase 3-ready cell therapy, and received FDA's Regenerative Medicine Advanced Therapy designation. Financially, the company holds $115 million in cash, projecting operational funding into Q2 2023, despite a net loss of $0.09 per share.